Nawgen LLC

Cellatrix LLC is a biotechnology company based in Saint Louis, Missouri, dedicated to advancing scientific research and drug development for the betterment of patient care. Their groundbreaking 3D-culture systems provide a physiologically relevant environment that accurately replicates the complex biology of the bone marrow microenvironment, particularly in hematological malignancies like Multiple Myeloma. Through partnerships with Azab Lab at Washington University in St. Louis and Biogenerator, Cellatrix is at the forefront of innovative research and development, aiming to revolutionize biological research, drug discovery, and personalized medicine. With a strong focus on both basic and translational approaches, Cellatrix is committed to making a significant impact in the field of biotechnology.Generated from the website

Accuronix Therapeutics Inc is a cutting-edge biotechnology company based in St. Louis, MO, dedicated to developing innovative cancer therapies. Utilizing a unique drug-targeting technology, the company focuses on addressing the most challenging issues in cancer treatment, with an initial emphasis on pancreatic cancer. With strategic partnerships with renowned institutions like Washington University and the University of Pennsylvania, Accuronix Therapeutics aims to develop groundbreaking oncology therapies that selectively target -2 receptors, which are known to be overexpressed on cancer cells. Led by President and CEO Bradley T. Keller, Ph.D., the company is committed to pushing the boundaries of cancer therapy and making a significant impact in the field of oncology.Generated from the website

Likarda, Inc. is a leading biotech company based in Kansas City, MO, specializing in the development of innovative technologies for the delivery of cell therapies, large molecules, and traditional drugs. Their Core-Shell Spherification (CSS) technology platform enhances therapeutic efficacy and provides sustainable solutions for chronic or life-threatening diseases. At the forefront of Likarda's innovation is the CSS technology, which coats cells and biologics with inert materials to ensure they remain at their intended location within the body, shielded from rejection, and releasing therapeutic payloads in a customized manner. This technology also protects cells during freezing and thawing, optimizing their functionality for patient administration.Generated from the website